| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000036326 |
| Receipt No. | R000041385 |
| Scientific Title | Radiotherapy for prostate cancer: Influence of fiducial marker on diffusion weighted MR image |
| Date of disclosure of the study information | 2019/03/28 |
| Last modified on | 2020/12/08 (Ver. 2) |
| Basic information | ||
| Public title | Radiotherapy for prostate cancer: Influence of fiducial marker on diffusion weighted MR image | |
| Acronym | Influence of Gold marker to MRI | |
| Scientific Title | Radiotherapy for prostate cancer: Influence of fiducial marker on diffusion weighted MR image | |
| Scientific Title:Acronym | Influence of Gold marker to MRI | |
| Region |
|
|
| Condition | ||||
| Condition | Prostate cancer | |||
| Classification by specialty |
|
|||
| Classification by malignancy | Malignancy | |||
| Genomic information | NO | |||
| Objectives | |
| Narrative objectives1 | If the background of DWI imaging differs by placing a gold marker before radiation treatment, there is a possibility that correct evaluation can not be made. This time we examined prospectively. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | The MR images taken before and after placement of the gold marker are compared and scored in five steps up to 1-5. If the point difference is large, it is determined that the gold marker affected the MR image. If there is no significant point difference, it is judged that there was no effect. |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Self control |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Diagnosis | |
| Type of intervention |
|
|
| Interventions/Control_1 | MR image | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male | |||
| Key inclusion criteria | Patients who can place gold markers in the prostate
Patients for whom informed consent was obtained |
|||
| Key exclusion criteria | Patients taking anticoagulant medication | |||
| Target sample size | 20 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Asahi University | ||||||
| Division name | Radiation Oncology | ||||||
| Zip code | 5008523 | ||||||
| Address | 3-23 Hashimoto-cho Gifu | ||||||
| TEL | 0582538001 | ||||||
| c.bluered@gmail.com | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Asahi University Hospital | ||||||
| Division name | Radiation Oncology | ||||||
| Zip code | 5008523 | ||||||
| Address | 3-23 Hashimoto-cho | ||||||
| TEL | 0582538001 | ||||||
| Homepage URL | |||||||
| c.bluered@gmail.com | |||||||
| Sponsor | |
| Institute | Asahi University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Asahi University |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Asahi University |
| Address | 3-23 Hashimoto-cho Gifu |
| Tel | 0582538001 |
| c.bluered@gmail.com | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000041385 |